On October 17, Qidu Pharma held its 2026 Quality Management Work Conference and the Second Expanded Meeting of the Drug Safety Committee. The conference reviewed the quality management work over the past decade, particularly in the current year, as well as the implementation of Quality Month activities, provided an in-depth analysis of the new situation and requirements arising from various quality complaints and GMP inspections in recent years, and outlined arrangements for the next phase of quality management work. Jiaqing Zheng, Secretary of the Party Committee, attended the meeting and delivered a speech. Jianyong Zhang, Board Chairman and General Manager, presided over the meeting. Xu Dong, Deputy General Manager and Quality Head, Lizhu Fan, Division Manager of Production and Engineering Equipment, and Yongliang Zhang, Manager of the New Business Department, delivered special reports. Da Xu, Deputy Director of the Technical Quality Department, presented the summary report on Quality Month activities. Group leaders presented awards to the outstanding organizing units of Quality Month activities and the winning units of the GMP Knowledge Competition. Leaders of the Group and the Company, principal heads and quality heads of subsidiary business divisions, and heads of units related to the quality system attended the meeting.
In his speech, Jiaqing Zheng affirmed the successful organization of Quality Month activities and extended congratulations to the award-winning units. He analyzed the current situation facing the pharmaceutical industry and the injections sector, noting that the industry is experiencing an obvious and accelerating trend of polarization. As high-risk products, injections are subject to increasingly stringent national regulatory standards and strengthened penalties. Only enterprises with strong quality and safety assurance capabilities, strong innovation capabilities, and strong compliance management capabilities can survive in the fierce market competition and achieve sustained, stable, and healthy development.
Drawing on reflections and warnings from recent quality complaints and new situations and trends in GMP inspections, he offered guidance on the priorities of quality management work for the period ahead:
First, earnestly review lessons learned and firmly hold the red line and bottom line of quality management. Second, consistently uphold the "Four Strictest" requirements and implement a one-vote veto system for quality issues. Third, introduce and apply modern tools to enhance the quality and efficiency of quality management work. Fourth, effectively address shortcomings and weaknesses to truly achieve full coverage of quality management. Fifth, benchmark against industry-leading standards and accelerate the internationalization of quality management.
He emphasized the need to continuously strengthen the quality system, institutional framework, and team building, actively cultivate and recruit leading quality management talent, and strive to achieve the company’s first FDA and PIC/S certification for both finished dosage forms and API. He expressed the hope that all personnel within the quality management system, especially the responsible persons, must clearly understand the new situation, fulfill their primary responsibilities, dare to confront difficult issues head-on, accelerate standardization and improvement, and strive for first-class standards.
While presiding over the meeting, Jianyong Zhang pointed out that drug quality concerns patient safety and is an impassable red line for the enterprise, as well as the foundation for its survival and long-term development. This conference serves not only as a summary meeting for Quality Month activities but also as a warning meeting for effective GMP implementation and a deployment meeting for quality management work.
He offered suggestions on quality management for products with special requirements, investigation and rectification of quality issues, understanding of new regulatory requirements, and organizational structure adjustment of the quality management department, and put forward requirements for the next phase of quality management work:
First, strictly implement closed-loop rectification. Adhere to the principle of not letting matters rest until problems are thoroughly investigated, rectification is fully implemented, responsibilities are fulfilled, and lessons are learned. Second, continuously improve the GMP quality management system. Strengthen lifecycle management of changes, deviations, OOS/OOT, and complaints, conduct regular internal self-inspections, proactively identify system hazards, and continuously enhance system effectiveness. Third, firmly hold the bottom line of quality compliance. Adhere to the principle of no production without compliance and no operations without compliance, and treat quality compliance as the prerequisite for all work. Fourth, strive to achieve the company’s first US FDA and EU certification to provide strong support for the company's international development.
Xu Dong delivered a thematic report titled "Confronting Problems to Strengthen the System, Full-Process Control to Promote Quality Improvement." She reviewed the quality management work of the past decade, summarized experience and achievements in quality system improvement, quality enhancement, institutional development, and team building, analyzed typical cases for warning and reflection, and outlined arrangements for the next phase of quality management improvement. She emphasized that quality management must resolutely implement the "Four Strictest" requirements, use the "Three-All and One-Intelligent" quality management model as the cornerstone, continuously improve the quality management system and pharmacovigilance system, cascade and solidify primary responsibilities across the entire drug lifecycle, systematically prevent and mitigate quality and safety risks, safeguard public medication safety, and protect the company's high-quality development.
At the meeting, Lixin Yu, Director of the Quality Inspection Center; Jiqiang Li, Director of the Pharmacovigilance Center; Yu Tie, Deputy Director of the Production and Engineering Equipment Department; Ningbo Wang, Director of Workshop 305; Min Zhai, Director of Registration and Technology Cooperation Department; Hongxia Cao, Director of the Storage and Transportation Center; Bingyue Shi, Deputy General Manager of the API Business Division; and Hao Kong, Executive Deputy General Manager of the Modern Chinese Traditional Medicine Business Division, delivered exchange speeches.
Recommended reading
-
January 20, 2025Top Ten Events of Qidu Pharmaceutical Group in 2025 Announced
-
June 17, 2026Qidu Pharma’s intelligent production project for oral preparations with an annual capacity of 10 billion tablets/granules passed the GMP on-site inspection.
-
November 09, 2026“International Qidu · English Leads the Future” Series of Internationalization-Themed Activities Officially Launched
-
November 09, 2026Qidu Pharma’s First Drug-Loaded Lipid Emulsion Product, Aprepitant Injection, Approved for Marketing
-
November 09, 2026Qidu Pharmaceutical Group Makes a Strong Showing at Both CPHI Milan and PharmChina in Beijing
-
October 13, 2026Qidu Pharmaceutical Holds Postdoctoral Completion and Entry Ceremony and Project Report Meeting
-
October 13, 2026Qidu Metrology and Testing Center Passes CNAS Calibration Laboratory On-Site Assessment